These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 37451337)
1. Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. Vilarrasa E; Nicolau J; de la Cueva P; Goday A; Gallardo F; Martorell A; Carrascosa JM Actas Dermosifiliogr; 2024 Jan; 115(1):56-65. PubMed ID: 37451337 [TBL] [Abstract][Full Text] [Related]
2. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100 [TBL] [Abstract][Full Text] [Related]
3. [A new era for glucagon-like peptide-1 receptor agonists]. Neuville MF; Paquot N; Scheen AJ Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066 [TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390 [TBL] [Abstract][Full Text] [Related]
5. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Ard J; Fitch A; Fruh S; Herman L Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495 [TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity. Jensterle M; Janež A Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347 [TBL] [Abstract][Full Text] [Related]
7. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. Fernández-García JC; Colomo N; Tinahones FJ Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723 [TBL] [Abstract][Full Text] [Related]
9. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Isaacs D; Prasad-Reddy L; Srivastava SB Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314 [No Abstract] [Full Text] [Related]
11. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411 [TBL] [Abstract][Full Text] [Related]
12. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736 [TBL] [Abstract][Full Text] [Related]
13. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Burcelin R; Gourdy P Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208 [TBL] [Abstract][Full Text] [Related]
14. GLP-1 agonists for people living with HIV and obesity, is there a potential? Zino L; Tack CJ; Richel O; Burger DM HIV Med; 2023 Oct; 24(10):1029-1034. PubMed ID: 37340561 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Amaro A; Sugimoto D; Wharton S Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309 [TBL] [Abstract][Full Text] [Related]
16. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653 [TBL] [Abstract][Full Text] [Related]
17. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Iepsen EW; Torekov SS; Holst JJ Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933 [TBL] [Abstract][Full Text] [Related]
18. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Popoviciu MS; Păduraru L; Yahya G; Metwally K; Cavalu S Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445623 [TBL] [Abstract][Full Text] [Related]
19. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Iepsen EW; Torekov SS; Holst JJ Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877 [TBL] [Abstract][Full Text] [Related]